Quantcast

Industry news that matters to you.  Learn more

KineMed Awarded NIH Contract to Identify Biomarkers for Myocardial Fibrosis

Reading time: 2 – 3 minutes

KineMed, Inc. (www.kinemed.com) recently announced that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded the company a Phase I SBIR (Small Business Innovation Research) contract to develop biomarkers for the detection of early myocardial fibrosis. Biomarkers for myocardial fibrosis will guide disease interventions that block the progression of this disease which is risk factor for heart failure and arrhythmias.

The goal of this $225,000 contract is to significantly advance non-invasive methods to detect, and monitor myocardial fibrosis in vivo. Early detection of myocardial fibrosis is essential to the development of effective ways to diagnose, treat, and prevent fibrotic cardiac disorders. Current methods of detection are either invasive biopsy-based tests or are unable to detect fibrogenesis in its early stages.

“We are gratified to acknowledge this award from the NIH SBIR program to advance KineMed’s development of non-invasive biomarkers for myocardial fibrosis,” said Dr. Scott Turner, Executive Vice-President, R&D at KineMed. “KineMed’s Dynamic Proteomics technology allows the discovery and development of novel protein biomarker targets based on changes in their synthesis and breakdown rates, thereby overcoming many of the limitations of static, conventional proteomic measurements. When applied to blood proteins, Dynamic Proteomics has led to the discovery of non-invasive markers of the protein synthesis that correlate directly to the fibrotic process in remodeling heart tissue, creating a “virtual biopsy” of intra-cardiac pathogenic processes from patient blood samples.”

“Under this grant, KineMed will identify and validate novel plasma biomarkers of myocardial fibrosis that will be tested in humans, with the goal of developing clinical biomarkers and diagnostic tests. A simple blood-based measurement to accurately assess myocardial fibrogenesis would be a significant advance in the ability to develop effective therapeutics, identify appropriate patients for treatments, and monitor response to therapy in clinical trials as well as routine medical care. We thank the NIH and are proud to be collaborating on an initiative that can potentially bring benefit to millions of Americans threatened by fibrotic disease.”

Source: KineMed